Stockscreener 앱 받기
36.10
0.39%
-0.1345
Ultragenyx Pharmaceutical Inc 주식(RARE)의 최신 뉴스
Ultragenyx Pharmaceutical (RARE): Reassessing Valuation After Recent Share Price Rebound - Yahoo Finance
Frazier Life Sciences Management L.P. Acquires 325,000 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceutical Inc (RARE) - GuruFocus
Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 3,081 Shares - MarketBeat
Ultragenyx (RARE) CFO Horn sells $112k in stock By Investing.com - Investing.com Canada
Ultragenyx (RARE) CFO Horn sells $112k in stock - Investing.com
Is Ultragenyx Pharmaceutical (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts? - Yahoo Finance
Is Ultragenyx Pharmaceutical Inc. (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts? - Insider Monkey
Bank of Nova Scotia Purchases Shares of 241,985 Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap UpTime to Buy? - MarketBeat
Norges Bank Invests $35.77 Million in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. $RARE Holdings Boosted by Hsbc Holdings PLC - MarketBeat
Is Ultragenyx Pharmaceutical Inc. stock near bottom after declineJuly 2025 Recap & Safe Investment Capital Preservation Plans - Newser
Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by Sands Capital Management LLC - MarketBeat
Schroder Investment Management Group Acquires 71,888 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Will Ultragenyx Pharmaceutical Inc. (UP0) stock attract long term capital inflowsLong Setup & Expert Verified Movement Alerts - Newser
Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight - Yahoo Finance Singapore
RARE: Phase 3 data in rare diseases and gene therapy filings are set to drive growth this year - TradingView
Skandinaviska Enskilda Banken AB publ Has $2.46 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Capital Fund Management S.A. Buys 43,903 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 03 - marketscreener.com
Loomis Sayles & Co. L P Reduces Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Can Ultragenyx Pharmaceutical Inc. (UP0) stock surprise with quarterly resultsJuly 2025 Breakouts & Daily Volume Surge Signals - Newser
Legal & General Group Plc Purchases 54,837 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Will Ultragenyx Pharmaceutical Inc. (UP0) stock hit Wall Street targets2025 Valuation Update & Precise Buy Zone Tips - Newser
Franklin Resources Inc. Decreases Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ultragenyx (RARE): Assessing Valuation as Revenue Growth and Clinical Progress Fuel Renewed Investor Interest - Yahoo Finance
Ultragenyx Shares Rally After FDA Updates Are They Priced Right for 2025? - Yahoo Finance
Ultragenyx Pharmaceutical (RARE): Evaluating Valuation After Analyst Commentary on Setrusumab Progress and Growth Outlook - Sahm
Barclays Remains Cautious on Ultragenyx (RARE), Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook - MSN
Ultragenyx to Participate in Investor Conferences in December - Sahm
Rhenman & Partners Asset Management AB Grows Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Bear Alert: Will Ultragenyx Pharmaceutical Inc. stock see PE expansion2025 Earnings Surprises & Low Risk Entry Point Tips - BỘ NỘI VỤ
Is Ultragenyx Pharmaceutical Inc. stock positioned well for digital economyTake Profit & Accurate Entry/Exit Alerts - moha.gov.vn
Why Ultragenyx Pharmaceutical Inc. stock is favored by top institutionsNew Guidance & Daily Chart Pattern Signal Reports - moha.gov.vn
Barclays Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $3.28 Million Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. $RARE Shares Acquired by Geode Capital Management LLC - MarketBeat
Barclays Maintains Ultragenyx Pharmaceutical (RARE) Overweight Recommendation - Nasdaq
Ultragenyx (NASDAQ: RARE) to join Citi, Evercore healthcare investor conferences - Stock Titan
RARE: Barclays Lowers Price Target Amid Maintaining Overweight R - GuruFocus
Connor Clark & Lunn Investment Management Ltd. Lowers Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ultragenyx Pharma stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Australia
0.56%
1.23%
자본화:
|
볼륨(24시간):